Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Reslizumab (Primary)
- Indications Churg-Strauss syndrome; Granulomatosis
- Focus Adverse reactions
- Acronyms RITE
- 12 Sep 2017 Status changed from not yet recruiting to recruiting.
- 27 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.
- 03 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.